GlassScriptPhysician profile
Michael Muzoora
NPI 1629237458
$17,857.52
in general payments reported to CMS, 2019-2025
39 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,485 · 2020: $567 · 2021: $461 · 2022: $1,200 · 2023: $11K · 2024: $1,811 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,110 · Food and Beverage: $5,007 · Travel and Lodging: $3,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,110.48 |
| Food and Beverage | $5,006.56 |
| Travel and Lodging | $3,027.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,852.48 | 2023 | Da Vinci Surgical System |
| Penumbra, INC. | $2,821.37 | 2023 | Indigo System, Penumbra System, Ruby Coil |
| Glaxosmithkline, LLC. | $1,527.87 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,479.06 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Actelion Pharmaceuticals US, INC. | $816.56 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $538.94 | 2019-2025 | Ofev |
| Sunovion Pharmaceuticals INC. | $400.72 | 2019-2020 | |
| Insmed, INC. | $387.14 | 2019-2025 | Arikayce |
| Genzyme Corporation | $333.22 | 2019-2025 | |
| Olympus America INC. | $320.64 | 2022-2025 | Spiration Valve System, Spin Thoracic Navigation System, 120v, 60hz |
| Gilead Sciences, INC. | $222.31 | 2022-2024 | Veklury |
| Electromed, INC. | $220.35 | 2019-2024 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $218.55 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $210.56 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $182.87 | 2019-2024 | Yupelri |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $152.31 | 2022-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $102.23 | 2024-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Livanova USA, INC. | $90.51 | 2023 | Lifesparc |
| Harmony Biosciences LLC | $88.98 | 2021-2025 | |
| Genentech USA, INC. | $86.56 | 2019-2023 | Xolair |
| Merck Sharp & Dohme LLC | $84.46 | 2022-2025 | Zerbaxa, Recarbrio, Capvaxive |
| Philips North America LLC | $79.92 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Teva Pharmaceuticals USA, INC. | $78.89 | 2019-2023 | Cinqair |
| Novartis Pharmaceuticals Corporation | $72.58 | 2019 | |
| Inari Medical, INC. | $71.90 | 2021 | |
| Csl Behring | $42.12 | 2019-2022 | |
| Baxter Healthcare | $39.97 | 2024-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $33.75 | 2025 | Yupelri |
| Abiomed | $30.17 | 2022 | |
| Mayne Pharma Commercial LLC | $27.25 | 2020 | |
| Mallinckrodt Hospital Products INC. | $25.86 | 2023 | Acthar |
| Veran Medical Technologies, INC. | $24.49 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.52 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $18.12 | 2025 | Lumryz |
| Allergan, INC. | $16.43 | 2019 | |
| Siemens Medical Solutions USA, INC. | $14.39 | 2024 | Cios Spin |
| Resmed Corp | $14.14 | 2021 | |
| Pfizer INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Muzoora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.